A recent study reveals that individuals who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise programs.
Findings released in a major medical journal demonstrates that while obese people can lose about a fifth of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these treatments must be cognizant of the potential of fast weight regain when the medication concludes," warns expert Dr. Susan Jebb.
That rate of recovery means a reversion to starting mass within about one and a half years.
Weighing Approaches
The analysis, which looked at 37 of studies involving over 9,000 of participants, contrasted the effects of these new drugs with other pills.
The team point out that people who shed pounds through diet and exercise typically have a less rapid creep back—perhaps 0.1 kg a month—after stopping.
Explaining the Fast Rebound
Experts believe the mechanism of the jabs is key to understanding the amplified rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 levels several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to hunger is no longer kept in check, making overeating far more likely."
A Chronic Disease?
The NHS advise the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals argue that, due to the likelihood of relapse, the treatment is often ongoing.
This opinion is reinforced by drug manufacturers, who note that the findings "highlight the persistent nature of obesity," akin to managing diseases like hypertension.
User Accounts
Users who have come off the jabs report a powerful return of appetite.
"It was like a trigger flipping and you're instantly ravenous," described a patient.
The struggle is exacerbated if individuals have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Use
Figures indicate that a significant number of adults in the UK have tried these injections in the past year, with demand being substantial.
- Adoption is more common among females than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while these medications are potent tools for shedding pounds, they are not a magic cure and long-term success likely depends on ongoing behavioural management.
